用于检测、定量和定位抗原与抗体的技术——ELISA、免疫印迹、免疫组化与流式细胞术。以下是我们知识库中标注该主题的实验方案、常见问题与技术文章。
Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ADCs ...
抗体偶联药物（antibody–drug ...
Antibody–drug conjugates (ADCs) use tumor cell-surface antigens to achieve antibody recognition and payload delivery. HER2, TROP2, Nectin-4, FRα, and c-Met have received substantial clinical validation, while HER3, B7-H3, CLDN18.2, and DLL3 continue to enter ADC development pipelines. The ...
抗体药物偶联物（Antibody–Drug Conjugate，ADC）由三部分组成：单克隆抗体、连接子（Linker）和细胞毒性载荷（Payload）。抗体负责识别肿瘤相关抗原，Payload 负责杀伤细胞，Linker 则决定 Payload ...
Antibody–drug conjugates (ADCs) consist of three components: a monoclonal antibody, a linker, and a cytotoxic payload. The antibody is responsible for recognizing tumor-associated antigens, the payload is responsible for killing cells, and the linker determines whether the payload can be safely ...
Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ADCs ...
Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ADCs ...
Antibody-coupled drug ADCs are a hot frontier in cancer therapy, providing a targeted therapy approach that combines the specificity of monoclonal antibodies with the potency of cytotoxic agents.
抗体偶联药物ADC是癌症治疗中当下非常火热的前沿领域，它提供了一种结合单克隆抗体特异性和细胞毒性药物效力的靶向治疗方法。
常与免疫学实验一起研究的技术。
危险品化学品经营许可证（带存储）